Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical properties following intravitreal ocriplasmin injection for vitreomacular traction. Methods: This is an interventional comparative case series of 12 surgically excised ILM specimens consecutively obtained from 9 eyes of 9 patients after unsuccessful pharmacologic vitreolysis with ocriplasmin. During the same time period, 16 specimens from 13 other eyes without ocriplasmin treatment were harvested during vitrectomy and served as controls. All patients presented with macular holes or vitreomacular traction and underwent vitrectomy with ILM peeling either with or without brilliant blue (BB) staining. All specimens were analyzed using atomic force microscopy with scan regions of 25 × 25 μm. In all specimens, both the retinal side and vitreal side of the ILM were analyzed. Results: Atomic force microscopy revealed no significant differences in elasticity of ILM specimens removed from eyes with or without ocriplasmin treatment. Undulated areas of the retinal side presented stiffer than the vitreal side of the ILM. Topographical mapping of both the vitreal and retinal side of the ILM showed no apparent alteration of the morphology in ocriplasmin-treated eyes compared to untreated eyes. Staining with BB resulted in an increase of tissue stiffness. Conclusions: Intravitreal injection of ocriplasmin does not change biomechanical properties of the human ILM. There is no evidence of a potential enzymatic effect of ocriplasmin interfering with the stiffness of this basement membrane.

Keywords:
Internal limiting membrane, Ocriplasmin, Vitreomacular traction
1.
Gandorfer A, Rohleder M, Sethi C, et al: Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-647.
2.
Stalmans P, Benz MS, Gandorfer A, et al; MIVI-TRUST Study Group: Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606-615.
3.
Bartz-Schmidt K-U, Bertram B, Bornfeld N, et al: Current Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for therapeutic intravitreal application of Ocriplasmin (JETREA®) in ophthalmology (May 2013) (in German). Klin Monbl Augenheilkd 2013;230:629-634.
4.
Stalmans P, Duker JS, Kaiser PK, et al: OCT-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 2013;33:2003-2011.
5.
Haller JA, Stalmans P, Benz MS, et al: Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion. Subgroup analyses from two randomized trials. Ophthalmology 2015;122:117-122.
6.
Kaiser PK, Kampik A, Kuppermann BD, et al: Safety profile of ocriplasmin for pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina 2015;35:1111-1127.
7.
Maier M, Abraham S, Frank C, Feucht N, Lohmann CP: Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences (in German). Ophthalmologe 2015;112:990-994.
8.
Halfter W, Oertle P, Monnier CA, et al: New concepts in basement membrane biology. FEBS J 2015;282:4466-4479.
9.
Halfter W, Candiello J, Hu H, et al: Protein composition and biomechanical properties of in vivo-derived basement membranes. Cell Adh Migr 2013;7:64-71.
10.
Haritoglou C, Mauell S, Benoit M, et al: Vital dyes increase the rigidity of the internal limiting membrane. Eye 2013;27:1308-1315.
11.
Henrich PB, Monnier CA, Halfter W, et al: Nanoscale topographic and biomechanical studies of the human internal limiting membrane. Invest Ophthalmol Vis Sci 2012;53:2561-2570.
12.
Marshall GE, Konstas AG, Bechrakis NE, Lee WR: An immunelectron microscope study of the aged human lens capsule. Exp Eye Res 1992;54:393-401.
13.
Slattery AD, Blanch AJ, Quinton JS, Gibson CT: Accurate measurement of Atomic Force Microscope cantilever deflection excluding tip-surface contact with application to force calibration. Ultramicroscopy 2013;131:46-55.
14.
Bilodeau GG: Regular pyramid punch problem. J App Mech 1992;59:519-523.
15.
Hertz H: Über die Berührung fester elastischer Körper. Journal für reine und angewandte Mathematik 1881;92:156-171.
16.
Hahn P, Chung MM, Flynn HW, et al: Safety profile of ocriplasmin for symptomatic vitreomacular adhesion. A comprehensive analysis of premarketing and postmarketing experiences. Retina 2015;35:1128-1134.
17.
Tibbetts MD, Reichel E, Witkin AJ: Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol 2014;132:487-490.
18.
Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM: Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 2015;99:635-638.
19.
Casswell E, Fernandez-sanz G, Mitry D, Luk S, Zakir R: Macular hole progression following ocriplasmin intravitreal injection. Case Rep Ophthalmol Med 2014;2014:403461.
20.
Johnson MW: Acute ocriplasmin retinopathy. Retina 2015;35:1055-1058.
21.
Fahim AT, Khan NW, Johnson MW: Acute panretinal structural and functional abnormalities after intravitreal ocriplasmin injection. JAMA Ophthalmol 2014;132:484-486.
22.
Beebe DC: Understanding the adverse effects of ocriplasmin. JAMA Ophthalmol 2015;133:229-231.
23.
Singh RP, Li A, Debi R, et al: Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 2014;98:356-360.
24.
Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP: Assessment of retinal alterations after intravitreal ocriplasmin with spectral domain-optical coherence tomography. Ophthalmology 2014;121:2506-2507.e2.
25.
Warrow DJ, Lai MM, Patel A, et al: Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 2015;159:20-30.
26.
Chen W, Mo W, Sun K, et al: Microplasmin degrades fibronectin and laminin at the vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res 2009;34:1057-1064.
27.
Libby RT, Champliaud MF, Claudepierre T, et al: Laminin expression in adult and developing retinae: evidence of two novel CNS laminins. J Neurosci 2000;20:6517-6528.
28.
Libby RT, Lavallee CR, Balkema GW, et al: Disruption of laminin beta2 chain production causes alterations in morphology and function in the CNS. J Neurosci 1999;19:9399-9411.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.